Clinical Trial Update: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selinexor as monotherapy in patients with JAK inhibitor-naïve myelofibrosis and thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Thrombocytopenia

Drugs mentioned

• XPOVIO (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Myelofibrosis, Moderate Thrombocytopenia | Phase 2 | Status: RECRUITING